Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19

Summary

Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been tested. In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding among mild to moderate COVID-19 patients, and in shortening the symptom resolution time.

Timeline

Start

2020-05-12

Primary completion

2020-09-30

Completion

2020-10-31

Drugs

Indications